aurobindo pharma

Buy Aurobindo Pharma; target of Rs 915: ICICI Direct

ICICI Direct is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 915 in its research report dated February 08, 2019.

Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings

Aurobindo has maintained its guidance of 30 percent YoY growth in injectable sales. Further, company filed 10 ANDAs, including 4 injectables, taking the cumulative ANDAs pending for approval to 122

Aurobindo acquires Apotex's ops in 5 European countries

The company had inked a binding agreement on July 14, 2018, to acquire five of Apotex' European businesses, including infrastructure, personnel, products, certain established trademarks, marketing authorisations and dossier licence rights in Poland, the Czech Republic, the Netherlands, Spain and Belgium, Aurobindo Pharma said in a regulatory filing.

Aurobindo Pharm Consolidated December 2018 Net Sales at Rs 5,269.67 crore, up 21.53% Y-o-Y

Aurobindo Pharm Standalone December 2018 Net Sales at Rs 3,248.10 crore, up 20.91% Y-o-Y

Aurobindo Pharma Q3 FY19 net profit zooms 19.7% to Rs 712.2 crore, beats analysts' estimates

The rise net profit was aided by strong performance of US, Europe, emerging markets and active pharmaceutical ingredients business. Favorable foreign exchange too added to the profit.

Buy Aurobindo Pharma; target of Rs 940: Motilal Oswal

Motilal Oswal is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 940 in its research report dated January 17, 2019.

Aurobindo Pharma Q3 PAT seen up 13.8% YoY to Rs. 669.1 cr: ICICI Direct

Net Sales are expected to increase by 15.8 percent Y-o-Y (up 5.7 percent Q-o-Q) to Rs. 5,022.3 crore, according to ICICI Direct.

Building speciality portfolio of around 150 products in next 3 fiscal yrs: Aurobindo

Commenting on the filing targets, Aurobindo said it plans to file all products over next 3 years in the oncology and hormones segment.

Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila

For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.

A morning walk down Dalal Street | Positive momentum possible only if Nifty holds 10,850

Most experts are of the view that as long as Nifty holds above 10800-10850, bulls should remain in charge of D-Street.

Aurobindo Pharma USA recalls 80 lots of blood pressure drug from America

The voluntary recall of Amlodipine Valsartan tablets USP, Valsartan HCTZ tablets USP and Valsartan tablets USP to the consumer level is due to the detection of trace amounts of an unexpected impurity found in the finished drug product, according to a release by the company posted on the website of the US Food and Drug Administration (USFDA).

'Nifty could go above 12,000 by 2019-end on accelerated earnings growth'

Harendra Kumar of Elara Capital said given the overall robustness in earnings recovery, 2019 could well be a year of midcaps and smallcaps.

Transcript| Aurobindo Pharma Q2 FY19 Earnings Conference Call

This is the verbatim transcript of Aurobindo Pharma management call with analysts.

Aurobindo Pharma gets USFDA nod for anaesthesia drug

The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Vecuronium Bromide Injection in the strengths of 10mg and 20mg, Aurobindo Pharma said in a BSE filing.

Aurobindo Pharma advances 2% on USFDA nod for anaesthesia drug

Aurobindo Pharma said Vecuronium Bromide will be launched in Q4FY19.

D-Street Buzz: Oil & gas stocks gain led by IOC, ONGC; Bharti Airtel spikes 4%, HDFC drags

The breadth of the market favoured the advances with 764 stocks advancing and 913 declining while 384 remained unchanged. On the BSE, 1157 stocks advanced, 1297 declined and 142 remained unchanged.

Aurobindo Pharma extends losses on report of a lawsuit against the co in US

The latest lawsuit is a part of growing litigation against the makers and distributors of sartan-based blood pressure lowering drugs in the US, the report said.

Pharma stocks poised for a bounceback; 3 bets for over 20% returns

In coming week any tick above 9,350 on Nifty Pharma index will trigger fresh buying in pharma stocks, Arpan Shah of Monarch Networth Capital said

Aurobindo Pharma expects first biosimilar approval in US in 12-18 months

A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company

These 3 Indian pharma firms to benefit from warning letter to Mylan's US facility

The slowdown in production at Morgantown site could provide a window of opportunity to Mylan's peers

Aurobindo Pharma to launch oncology, respiratory products in US by 2021

The company is also planning to launch first set of biosimilars and vaccines in growth markets during this time, Aurobindo Pharma said in an investor presentation.

Buy Aurobindo Pharma; target of Rs 875: HDFC Securities

HDFC Securities is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 875 in its research report dated November 14, 2018.

Buy Aurobindo Pharma; target of Rs 909: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 909 in its research report dated November 13, 2018.

Aurobindo inks pact to acquire Australian pharma firm's product

Aurobindo Pharma has said it's wholly-owned subsidiaryhas entered into an agreement to acquire a product under development and related assets from Australia-based Advent Pharmaceuticals Pty Ltd for USD 12.5 million.